CuraScientific (CuraScientific) Cash And Cash Equivalents : $0.04 Mil (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is CuraScientific Cash And Cash Equivalents?

CuraScientific's quarterly cash and cash equivalents increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.28 Mil) but then stayed the same from Jun. 2023 ($0.28 Mil) to Sep. 2023 ($0.04 Mil).

CuraScientific's annual cash and cash equivalents increased from Dec. 2020 ($0.01 Mil) to Dec. 2021 ($0.02 Mil) but then declined from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.00 Mil).

CuraScientific Cash And Cash Equivalents Historical Data

The historical data trend for CuraScientific's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific Cash And Cash Equivalents Chart

CuraScientific Annual Data

Trend

Dec20

Dec21

Dec22

Cash And Cash Equivalents

0.01

0.02

CuraScientific Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial							-	-	-	0.28	0.04

CuraScientific Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CuraScientific (OTCPK:CSTF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CuraScientific Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CuraScientific's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236

Website

https://www.curascientificcorp.com

CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.

Executives

Paul Quentin Goyette	director	2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed	director, officer: Chief Executive Officer	333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen	director	C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette	director	13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez	director, officer: Chief Executive Officer	15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson	director, officer: Chief Operating Officer	19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021